Schizophrenia News and Research

Latest Schizophrenia News and Research

Drug companies accused of skirting requirement to submit prices

Drug makers frequently ignore a federal requirement that they submit "pricing data needed to calculate discounts on medications prescribed for poor people under Medicaid, federal investigators say in a new report," The New York Times reports.

4 Oct 2010

Otsuka opens Canadian operations

Otsuka Canada Pharmaceutical Inc. has opened its first Canadian office, in the Montreal suburb of Saint-Laurent. This marks a major milestone in the continued growth of Otsuka in North America.

4 Oct 2010

IRSF awards $1.5M in research grants for Rett syndrome treatment

The International Rett Syndrome Foundation (IRSF) announced today that it will award an additional $1.5M in research grants, bringing the 2010 total to $2.15 million for innovative basic and translational research that moves treatments for Rett syndrome a step closer to the clinic.

4 Oct 2010

New SymPath kit measures DBH activity of Sympathetic Nervous System

Biotech Corporation in acquiring licenses to commercialize 12 Neuro-biomarkers has first focused on SymPath(R) and is now ready to give you the opportunity to shed some light about this Neuro-biomarker of the Sympathetic Nervous System (SNS). Here is a peak into the research behind the Neuro-blood testing that will be available to all patients through their health system.

4 Oct 2010

NIH to award $64M under Transformative Research Projects program

The National Institutes of Health will award up to $64 million over five years to encourage exploration of exceptionally innovative and original research ideas that have the potential for extraordinary impact.

4 Oct 2010

Cortex regains global rights to AMPAKINE compounds for treatment of schizophrenia and depression

Cortex Pharmaceuticals, Inc. announced that it has regained worldwide rights to develop and commercialize its AMPAKINE® compounds for the treatment of schizophrenia and depression.

1 Oct 2010

Intra-Cellular Therapies demonstrates ability of ITI-002 to improve motor and non-motor behaviors in PD

Intra-Cellular Therapies, Inc. today announced results from studies demonstrating the anti-Parkinson and other beneficial effects of ITI-002 (IC200214), the Company's novel and selective phosphodiesterase type I (PDE1) inhibitor.

1 Oct 2010

CSHL professor receives NIH grant to study mechanism behind autism and schizophrenia

Anthony Zador, Ph.D., Professor of Biology and Program Chair in Neuroscience at Cold Spring Harbor Laboratory (CSHL), has been awarded a $2.17 million, 5-year grant by the National Institutes of Health (NIH)'s Transformative Research Projects Program (T-R01).

1 Oct 2010

Study indicates neurotransmitters are abnormal in people with psychotic illness

There is growing evidence that two neurotransmitters - dopamine and glutamate - are abnormal in people with psychotic illness, including schizophrenia. Among many other things, these chemicals play a role in cognitive functions, such as memory, learning, and problem-solving.

1 Oct 2010

New approach to prevent psychotic symptoms

New research has linked psychosis with an abnormal relationship between two signalling chemicals in the brain. The findings, published in tomorrow's edition of the journal Biological Psychiatry, suggest a new approach to preventing psychotic symptoms, which could lead to better drugs for schizophrenia.

30 Sep 2010

Study suggests drugs targeting glutamatergic transmission may help treat psychotic illness

There is growing evidence that two neurotransmitters dopamine and glutamate are abnormal in people with psychotic illness, including schizophrenia. Among many other things, these chemicals play a role in cognitive functions, such as memory, learning, and problem solving.

30 Sep 2010

USC, Las Encinas Hospital to study on schizophrenia, bipolar disorder in younger, older adults

Schizophrenia and bipolar disorder affect 3% to 4% of the world's population, or about 222 million adults worldwide. In the United States, bipolar disorder affects about 5.7 million adult Americans 18 and older. Bipolar disorder, or manic depression, is a serious brain disorder that causes extreme shifts in mood, energy and functioning. People with the disorder experience episodes of mania and depression that can last from days to months. These symptoms usually begin in late adolescence, but can begin in early childhood or as late as a person's 40s or 50s. There is a strong genetic component related to bipolar disorder.

28 Sep 2010

Antipsychotics slightly raise risk for blood clots

Antipsychotics or medications that are used to treat psychiatric illnesses such as schizophrenia and bipolar disorder are reported to raise the risk of dangerous blood clots.

23 Sep 2010

Researchers explain how nerve cells transmit electrical signals

Billions of brain cells are communicating at any given moment. Like an organic supercomputer they keep everything going, from breathing to solving riddles, and "programming errors" can lead to serious conditions such as schizophrenia, Parkinson's disease and attention-deficit hyperactivity disorder.

22 Sep 2010

Haven Behavioral Hospital offers treatment programs for adults with psychiatric illnesses

Haven Behavioral Hospital of Eastern Pennsylvania announced today it is offering acute intensive, inpatient and partial day treatment programs for adults with major psychiatric illnesses. The hospital will operate within the downtown campus of St. Joseph Medical Center and will offer services for adults suffering from schizophrenia, bipolar disorder, depression and anxiety disorders.

21 Sep 2010

Arrayit installs microarray platform at NIH

Arrayit Corporation has completed installation and technical training of its proprietary microarray platform at the National Institute of Mental Health, National Institutes of Health, in Rockville, Maryland. In 2010, the NIH will invest more than $31.2 billion in medical research for the American people through 50,000 competitive grants to 325,000 researchers at 3,000 universities, hospitals, companies, medical schools and scientific institutions in the United States and around the world.

21 Sep 2010

Study examines effects of AEDs on nicotine metabolite levels in smokers

UMDNJ-Robert Wood Johnson Medical School researchers have determined that carbamazepine and oxycarbamazepine, medications commonly used to treat neurologic and psychiatric conditions, increase nicotine metabolism in smokers. As nicotine metabolism increases, cravings for nicotine return more quickly which could lead to more frequent cigarette consumption among individuals who also take these medications.

18 Sep 2010

Disabling RGS14 gene helps mice remember better

Deleting a certain gene in mice can make them smarter by unlocking a mysterious region of the brain considered to be relatively inflexible, scientists at Emory University School of Medicine have found.

18 Sep 2010

FDA Advisory Committee recommends approval of Alkermes' VIVITROL for opioid dependence

Alkermes, Inc. today announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee voted 12 to 1 that VIVITROL® (naltrexone for extended-release injectable suspension) should be approved for the treatment of opioid dependence.

17 Sep 2010

Researchers to contribute to brain circuit mapping in Human Connectome Project

Thirty-three researchers at nine institutions will contribute to the Human Connectome Project (http://www.humanconnectome.org/consortia). Using powerful, custom-built brain scanners, a supercomputer, new brain analysis techniques and other state-of-the-art resources, they will trace the anatomical 'wires' that interconnect thousands of different regions of the human brain's gray matter.

16 Sep 2010